Javascript must be enabled to continue!
Ivabradine Monotherapy for the Treatment of Congenital Junctional Ectopic Tachycardia in a Premature Neonate
View through CrossRef
Congenital junctional ectopic tachycardia is a rare and special type of supraventricular arrhythmia. Junctional ectopic tachycardia is characterized by persistently elevated heart rates that may cause an impairment in cardiac function. Junctional ectopic tachycardia is considered one of the most difficult-to-treat conditions even with a combination of antiarrhythmic medications. Ivabradine is a novel antiarrhythmic medication used to decrease the heart rate in adults with angina pectoris. We report a first case of a premature neonate with a normal heart structure who developed junctional ectopic tachycardia and was subsequently treated successfully with ivabradine.
The Pediatric Pharmacy Association
Title: Ivabradine Monotherapy for the Treatment of Congenital Junctional Ectopic Tachycardia in a Premature Neonate
Description:
Congenital junctional ectopic tachycardia is a rare and special type of supraventricular arrhythmia.
Junctional ectopic tachycardia is characterized by persistently elevated heart rates that may cause an impairment in cardiac function.
Junctional ectopic tachycardia is considered one of the most difficult-to-treat conditions even with a combination of antiarrhythmic medications.
Ivabradine is a novel antiarrhythmic medication used to decrease the heart rate in adults with angina pectoris.
We report a first case of a premature neonate with a normal heart structure who developed junctional ectopic tachycardia and was subsequently treated successfully with ivabradine.
Related Results
Ivabradine in the treatment of congenital junctional ectopic tachycardia: A systematic review
Ivabradine in the treatment of congenital junctional ectopic tachycardia: A systematic review
BACKGROUND
Congenital junctional ectopic tachycardia (CJET) is a rare but life-threatening arrhythmia in neonates and infants, often refractory to conventional antiarrhyt...
The Effect of Ivabradine on Hospitalization of Heart Failure Patients
The Effect of Ivabradine on Hospitalization of Heart Failure Patients
Background:
Ivabradine is recommended in heart failure (HF) patients to reduce cardiovascular death and hospitalization due to worsening of HF symptoms.
...
Abstract 18395: Safety of Continuing Ivabradine Treatment During Hospitalization for Worsening of Heart Failure in the SHIFT Study
Abstract 18395: Safety of Continuing Ivabradine Treatment During Hospitalization for Worsening of Heart Failure in the SHIFT Study
Background:
Chronic medical treatment is usually adapted during hospitalizations for worsening heart failure (HWHF). Ivabradine, a heart rate (HR)-slowing agent that in...
COMPARISON OF ORAL IVABRADINE AND METOPROLOL FOR CONTROL OF HEART RATE IN PATIENTS UNDERGOING CT CORONARY ANGIOGRAPHY
COMPARISON OF ORAL IVABRADINE AND METOPROLOL FOR CONTROL OF HEART RATE IN PATIENTS UNDERGOING CT CORONARY ANGIOGRAPHY
Objectives
Optimisation of heart rate (HR) to limit motion artefacts is mandatory in all patients undergoing CT coronary angiography (CTCA). Despite use of β-bloc...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta‐analysis of randomized controlled trials
Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta‐analysis of randomized controlled trials
Abstract
Elevated resting heart rate in chronic heart failure (HF) patients has been associated with higher mortality and poor prognosis. Iva...
Ivabradine Reduces Chemokine-Induced CD4-Positive Lymphocyte Migration
Ivabradine Reduces Chemokine-Induced CD4-Positive Lymphocyte Migration
Aims.Migration of CD4-positive lymphocytes into the vessel wall is a critical step in atherogenesis. Recent data suggest that ivabradine, a selective I(f)-channel blocker, reduces ...
Inadekvát, aránytalan sinuscsomó-tachycardia: egy régi szívritmuszavar új megvilágításban (II.)
Inadekvát, aránytalan sinuscsomó-tachycardia: egy régi szívritmuszavar új megvilágításban (II.)
Összefoglaló.
Bevezetés: Az inadekvát, aránytalan sinuscsomó-tachycardia a
szív nomotop ingerképzési zavarával járó, nem ritka klinikai szin...

